UK Food Standards Agency to modernise novel food authorisation process

The UK Food Standards Agency (FSA) is planning to update the authorisation process for novel foods in a bid to make it faster and more modern. Starting next year, changes will be introduced to improve the regulatory framework for market authorisations. These reforms aim to make approvals more efficient, especially for products like cultivated meat and those made using precision fermentation. During its latest board meeting, the FSA confirmed the creation of a new public register, which will replace the current requirement for a statutory instrument—a step that typically adds about six months to the approval timeline, which already spans more than two-and-a-half years. Following consultation with industry stakeholders and approval from the new Labour government, the regulator expects these changes to come into effect by early 2025.

This shift could benefit various stakeholders in the food industry while maintaining high safety standards. Notably, it also represents a step away from the EU-style regulations retained after Brexit, which the FSA suggests were not well-suited to the UK’s needs. Linus Pardoe, the UK policy manager at GFI Europe, expressed optimism about the changes, noting that British alternative protein companies might see this as a positive step towards streamlining the authorisation process, while still ensuring consumer safety. However, GFI Europe also highlighted the need for the UK to take even more ambitious actions to keep pace with global developments and urged the government to look at progressive regulatory models from other countries.

The proposed changes, originally put forward by the FSA in March, focus on “regulated products” such as feed additives, food flavourings, and alternative proteins. The regulator has proposed removing the renewal requirements for feed additives and food or feed containing genetically modified organisms (GMOs). Under the current system, products need to reapply for approval every ten years, which puts considerable pressure on the FSA’s resources, as about 22% of its current caseload involves renewal applications, with an additional 300 expected between 2025 and 2026.

The removal of the renewal requirement is intended to create a more proactive approach to food and feed safety, which will free up resources to focus on new authorisations, especially those for innovative products. Another significant proposal is to introduce a public register instead of requiring parliamentary approval through statutory instruments for novel foods. Removing this step is expected to accelerate the authorisation process by three months, allowing for the commercialisation of new products after ministerial approval.

Both proposals received substantial support, with around 71% of stakeholders agreeing with the plan to eliminate renewal requirements and 70% supporting the removal of the statutory instrument process. The FSA has stated that the reforms will make the regulatory system more efficient without compromising food safety standards, allowing consumers to access new and safe products faster. They also emphasised that these changes will allow them to focus on new marketing authorisations, including those for environmentally friendly products.

The regulatory adjustments come in the wake of progress made by London-based Meatly, the first European cultivated meat startup to secure regulatory clearance for its cultivated chicken products for cats and dogs. The approval was granted by the Department for Environment, Food and Rural Affairs. Other companies, such as Aleph Farms and Vital Meat, have also applied for cultivated meat authorisation in the UK, and Mosa Meat has expressed its intention to do the same. The FSA is keen to move beyond EU-inherited legislation, which they described as overly prescriptive and not always proportionate to the associated risks.

The agency has pointed out that its workload is expected to grow significantly, from 450 cases in March 2024 to 570 by March 2026. Without taking prompt action, it warned that it might be difficult to manage this growing workload, which could ultimately limit consumer access to new products. The FSA is also seeking government funding to create a regulatory ‘sandbox’ to facilitate the safety testing of cultivated meat. This initiative, backed by GFI Europe, could accelerate the understanding of the safety aspects of cultivated meat and is expected to be a part of the upcoming budget discussions.

While GFI Europe has welcomed the initial reforms, it has called for broader changes to modernise the UK’s regulatory framework for novel foods. Pardoe has emphasised that the government needs to quickly build on these initial steps, suggesting that an ambitious range of reforms is necessary to stay in line with rapid innovation. These could include providing clearer guidance for companies submitting applications, formalising the process for pre-submission consultations, and creating a system for pre-market tastings similar to those being developed in the Netherlands, which would allow companies to gather consumer feedback during product development.

BSF Enterprise plc (LON:BSFA), the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is unlocking the next generation of biotech solutions. It is achieving this through an acquisition-led growth strategy to drive the development of lab-grown tissues.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
BSF Enterprise plc

More articles like this

BSF Enterprise plc

The potential of cultivated meat in advancing sustainability

As COP 29 unfolds, there is growing hope that cultivated meat may finally gain the essential financial and regulatory support needed to achieve scalability and commercial success. Che Connon, managing director of BSF Enterprise and CEO

BSF Enterprise plc

Breakthrough in corneal regenerative therapies

Kerato’s innovative “biosynthetic cornea” provides a promising alternative to traditional donor corneal transplants. Designed for one-time use, this injectable device is administered single-handedly. It forms a self-sealing gel in the eye, which reduces inflammation, promotes tissue

BSF Enterprise plc

BSF Enterprise achieves Global Certification for Quality Management

BSF Enterprise, along with its subsidiaries, has recently achieved ISO 9001 certification, a globally recognised standard for quality management systems. This accomplishment signifies a strong commitment to quality across all areas of the company, reinforcing its

BSF Enterprise plc

A new standard in cell culture care with CytoBoost

CytoBoost is a new, premium approach to cell culture, offering laboratories a way to enhance the health and performance of their cells. With this innovative product, you can think of CytoBoost as a dedicated solution designed

BSF Enterprise plc

UK’s opportunity to lead in cell-grown meat production

Europe’s approach to the agri-tech revolution is increasingly viewed as outdated, with its regulations often criticised as overly protectionist and wary of technological advancements. The continent’s approach to cell-grown meat production mirrors this attitude, with the

BSF Enterprise plc

Advances in corneal transplants in ophthalmology

The aging global population is driving a rise in vision impairment, which in turn affects physical, cognitive, and mental health. Among the most commonly transplanted human tissues worldwide are corneas, with approximately 185,000 procedures performed annually.

BSF Enterprise plc

UK biotech company expands production of lab-grown leather

A UK-based biotech company recently achieved a significant milestone by producing a larger size of cultivated skin tissue at its laboratory in Newcastle. The company, Lab-Grown Leather (LGL), formerly known as 3D Bio-Tissues, is owned by

BSF Enterprise plc

Is artificial leather a viable alternative?

Artificial leather is often marketed as a more sustainable option compared to traditional leather, yet questions remain about whether it truly delivers on this promise. Environmental concerns still surround the production of artificial leather, particularly the

BSF Enterprise plc

Cultivated meat and its potential

Cultivated meat, also known as cultured meat, is real animal meat produced by cultivating animal cells directly, removing the need for traditional animal farming. This meat is composed of the same cell types as conventional meat,

BSF Enterprise plc

BSF Enterprise making strong progress across portfolio of companies

BSF Enterprise PLC (LON:BSFA), the parent to a portfolio of innovative subsidiary companies developing cell-based tissue engineering solutions to deliver sustainable outcomes across a variety of sectors, has provided the following portfolio update. ●     Lab Grown Leather (LGL): Revolutionising

BSF Enterprise plc

Lab-Grown Leather expands sustainable leather production capacity

Lab-Grown Leather Ltd (LGL) has made a significant step forward by increasing its production capacity for lab-grown leather. This development highlights the potential of their technology to revolutionise the leather industry, providing a sustainable and ethical